Matches in SemOpenAlex for { <https://semopenalex.org/work/W2132966952> ?p ?o ?g. }
Showing items 1 to 86 of
86
with 100 items per page.
- W2132966952 endingPage "161" @default.
- W2132966952 startingPage "154" @default.
- W2132966952 abstract "Yancey, M. F., Merritt, D. A., White, J. A., Marsh, S. A., Locuson, C. W. Distribution, metabolism, and excretion of toceranib phosphate (Palladia™, SU11654), a novel tyrosine kinase inhibitor, in dogs. J. vet. Pharmacol. Therap.33, 154–161. Toceranib phosphate (Palladia™, SU11654), a multireceptor tyrosine kinase inhibitor with anti-tumor and anti-angiogenic activity, has been developed for the treatment of mast cell tumors in dogs. An overview of the distribution, metabolism, and excretion of toceranib phosphate in dogs is presented. When [14C]-toceranib was orally administered to dogs, the majority of the radioactivity (92%) was excreted in feces and only a small portion (7%) was excreted in urine. Seven days after a single 3.25 mg/kg oral dose, radioactivity was the highest in bile and liver, with measurable concentrations in lymph nodes, colon, adrenals, bone marrow, kidneys, lungs, spleen, pancreas, and skin. Plasma protein binding of toceranib in fresh plasma ranged from 90.8% to 92.8% at concentrations between 20 ng/mL and 500 ng/mL and was independent of concentration. Microsomal and hepatocyte incubations resulted in the formation of a single metabolite. Spectrometric analysis of the metabolite was consistent with the formation of an alicyclic N-oxide of toceranib. The combination of the high rate of fecal excretion and the long elimination half-life of toceranib indicate enterohepatic recirculation of the parent compound and/or the N-oxide metabolite." @default.
- W2132966952 created "2016-06-24" @default.
- W2132966952 creator A5012971198 @default.
- W2132966952 creator A5013691152 @default.
- W2132966952 creator A5029872632 @default.
- W2132966952 creator A5031015047 @default.
- W2132966952 creator A5070272469 @default.
- W2132966952 date "2010-04-01" @default.
- W2132966952 modified "2023-09-27" @default.
- W2132966952 title "Distribution, metabolism, and excretion of toceranib phosphate (Palladia™, SU11654), a novel tyrosine kinase inhibitor, in dogs" @default.
- W2132966952 cites W1995227143 @default.
- W2132966952 cites W1998241556 @default.
- W2132966952 cites W2006809144 @default.
- W2132966952 cites W2027816981 @default.
- W2132966952 cites W2031564220 @default.
- W2132966952 cites W2060618580 @default.
- W2132966952 cites W2064350997 @default.
- W2132966952 cites W2098761057 @default.
- W2132966952 cites W2114017745 @default.
- W2132966952 cites W2119323720 @default.
- W2132966952 cites W2149908540 @default.
- W2132966952 cites W2487080409 @default.
- W2132966952 doi "https://doi.org/10.1111/j.1365-2885.2009.01120.x" @default.
- W2132966952 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20444040" @default.
- W2132966952 hasPublicationYear "2010" @default.
- W2132966952 type Work @default.
- W2132966952 sameAs 2132966952 @default.
- W2132966952 citedByCount "21" @default.
- W2132966952 countsByYear W21329669522012 @default.
- W2132966952 countsByYear W21329669522013 @default.
- W2132966952 countsByYear W21329669522014 @default.
- W2132966952 countsByYear W21329669522015 @default.
- W2132966952 countsByYear W21329669522016 @default.
- W2132966952 countsByYear W21329669522017 @default.
- W2132966952 countsByYear W21329669522018 @default.
- W2132966952 countsByYear W21329669522019 @default.
- W2132966952 countsByYear W21329669522020 @default.
- W2132966952 countsByYear W21329669522021 @default.
- W2132966952 crossrefType "journal-article" @default.
- W2132966952 hasAuthorship W2132966952A5012971198 @default.
- W2132966952 hasAuthorship W2132966952A5013691152 @default.
- W2132966952 hasAuthorship W2132966952A5029872632 @default.
- W2132966952 hasAuthorship W2132966952A5031015047 @default.
- W2132966952 hasAuthorship W2132966952A5070272469 @default.
- W2132966952 hasConcept C10146269 @default.
- W2132966952 hasConcept C126322002 @default.
- W2132966952 hasConcept C134018914 @default.
- W2132966952 hasConcept C185592680 @default.
- W2132966952 hasConcept C2777477808 @default.
- W2132966952 hasConcept C2778620825 @default.
- W2132966952 hasConcept C55493867 @default.
- W2132966952 hasConcept C62231903 @default.
- W2132966952 hasConcept C71924100 @default.
- W2132966952 hasConcept C86803240 @default.
- W2132966952 hasConceptScore W2132966952C10146269 @default.
- W2132966952 hasConceptScore W2132966952C126322002 @default.
- W2132966952 hasConceptScore W2132966952C134018914 @default.
- W2132966952 hasConceptScore W2132966952C185592680 @default.
- W2132966952 hasConceptScore W2132966952C2777477808 @default.
- W2132966952 hasConceptScore W2132966952C2778620825 @default.
- W2132966952 hasConceptScore W2132966952C55493867 @default.
- W2132966952 hasConceptScore W2132966952C62231903 @default.
- W2132966952 hasConceptScore W2132966952C71924100 @default.
- W2132966952 hasConceptScore W2132966952C86803240 @default.
- W2132966952 hasIssue "2" @default.
- W2132966952 hasLocation W21329669521 @default.
- W2132966952 hasLocation W21329669522 @default.
- W2132966952 hasOpenAccess W2132966952 @default.
- W2132966952 hasPrimaryLocation W21329669521 @default.
- W2132966952 hasRelatedWork W1978634877 @default.
- W2132966952 hasRelatedWork W2011971901 @default.
- W2132966952 hasRelatedWork W2021846613 @default.
- W2132966952 hasRelatedWork W2028993205 @default.
- W2132966952 hasRelatedWork W2041949500 @default.
- W2132966952 hasRelatedWork W2080366740 @default.
- W2132966952 hasRelatedWork W2154101925 @default.
- W2132966952 hasRelatedWork W2426717236 @default.
- W2132966952 hasRelatedWork W2437522509 @default.
- W2132966952 hasRelatedWork W4240148004 @default.
- W2132966952 hasVolume "33" @default.
- W2132966952 isParatext "false" @default.
- W2132966952 isRetracted "false" @default.
- W2132966952 magId "2132966952" @default.
- W2132966952 workType "article" @default.